Current Bladder Dysfunction Reports

, Volume 13, Issue 1, pp 8–12 | Cite as

Prevalence of Urgency in Patients with LUTS Due to BPE

BPH-Related Voiding Dysfunction (R Lee, Section Editor)
Part of the following topical collections:
  1. Topical Collection on BPH-Related Voiding Dysfunction

Abstract

Purpose of Review

To review recent data on the prevalence and treatment of the symptom of urgency in men with benign prostatic enlargement (BPE).

Recent Findings

In recent years, researchers have moved to separate out individual lower urinary tract symptoms (LUTS) to see the individual impact. A recent registry trial put the prevalence of urgency at 38% in men with BPE. Other studies have reported urgency present in 64% of men with LUTS. While urgency is not as frequent a complaint in BPE as nocturia and frequency, it does have an impact on health-related quality of life. It is not increased in men with diabetes or the metabolic syndrome. Contributing factors may include prostate inflammation and decreased bladder blood flow from outlet obstruction. While some response is seen with treatment with alpha-blockers, more recently, anticholinergic and beta 3 medications are being used for refractory urgency in men with BPE.

Summary

Urinary urgency is commonly reported in men with benign prostatic enlargement and is just beginning to be better evaluated with screening tools commonly used in overactive bladder patients. Specific medical therapy for urgency is helping to improve the response rate above traditional BPE therapy.

Keywords

Urgency BPH BPE LUTS Prevalence 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Sih and Dr. Angel have no conflicts of interest. Dr. Pontari was paid consultant fees from Aquinox and Allergen.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently have been highlighted as: •Of importance

  1. 1.
    Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031.  https://doi.org/10.1038/nrdp.2016.31.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017;7:7984.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.  https://doi.org/10.1002/nau.10052.CrossRefPubMedGoogle Scholar
  4. 4.
    Tam CA, Helfand BT, Erickson BA. The relationship between diabetes, diabetes severity, diabetes biomarkers, and the presence of lower urinary tract symptoms: findings from the national health and nutrition examination survey. Urology. 2017;105:141–8.  https://doi.org/10.1016/j.urology.2017.03.040.CrossRefPubMedGoogle Scholar
  5. 5.
    Gacci M, Corona G, Sebastianelli A, Serni S, de Nunzio C, Maggi M, et al. Male lower urinary tract symptoms and cardiovascular events: a systematic review and meta-analysis. Eur Urol. 2016;70(5):788–96.  https://doi.org/10.1016/j.eururo.2016.07.007.CrossRefPubMedGoogle Scholar
  6. 6.
    Helfand BT, McVary KT, Meleth S, Sharp V, Foster H, Naslund M, et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. J Urol. 2011;185(6):2223–8.  https://doi.org/10.1016/j.juro.2011.02.012.CrossRefPubMedGoogle Scholar
  7. 7.
    Jeong SM, Suh B, Jang SH, Jin HS, Kim N, Kwon H, et al. Depression and its severity are strongly associated with both storage and voiding lower urinary tract symptoms independently of prostate volume. J Korean Med Sci. 2015;30(11):1646–51.  https://doi.org/10.3346/jkms.2015.30.11.1646.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Russo GI, Cimino S, Fragalà E, Privitera S, La Vignera S, Condorelli R, et al. Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. World J Urol. 2015;33(5):743–51.  https://doi.org/10.1007/s00345-014-1392-4.CrossRefPubMedGoogle Scholar
  9. 9.
    Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14.  https://doi.org/10.1016/j.eururo.2006.09.019.CrossRefPubMedGoogle Scholar
  10. 10.
    Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009;56(1):14–20.  https://doi.org/10.1016/j.eururo.2009.02.026.CrossRefPubMedGoogle Scholar
  11. 11.
    Miranda Ede P, Gomes CM, Torricelli FC, Júnior d BJ, de Castro JE, Ferreira BR, et al. Nocturia is the lower urinary tract symptom with greatest impact on quality of life of men from a community setting. Int Neurourol J. 2014;18(2):86–90.  https://doi.org/10.5213/inj.2014.18.2.86.CrossRefPubMedGoogle Scholar
  12. 12.
    • Rohrmann S, Katzke V, Kaaks R. Prevalence and progression of lower urinary tract symptoms in an aging population. Urology. 2016;95(158):158–63.  https://doi.org/10.1016/j.urology.2016.06.021. This study followed lower urinary tract symptoms and demonstrated both improvement and worsening of symptoms over a 3-year period, reinforcing that LUTS are not static and are prone to change.CrossRefPubMedGoogle Scholar
  13. 13.
    Cambronero J, Arlandis S, Errando C, Mora AM. Profile of lower urinary tract symptoms in the male and their impact on quality of life. Actas Urol Esp. 2013;37:401.CrossRefPubMedGoogle Scholar
  14. 14.
    Tubaro A, Berges R, Caris C, De la Taille A, Esperto F, Martinez-Pinero L, et al. The prevalence of urgency in patients with lower urinary tract symptoms due to benign prostatic enlargement. Analysis of the Evolution Registry. J. Urol. 2016;195(suppl 4S):e480. Abstract MP35-06.  https://doi.org/10.1016/j.juro.2016.02.1598.Google Scholar
  15. 15.
    Bang WJ, Lee JY, Koo KC, Hah YS, Lee DH, Cho KS. Is type-2 diabetes mellitus associated with overactive bladder symptoms in men with lower urinary tract symptoms? Urology. 2014;84(3):670–4.  https://doi.org/10.1016/j.urology.2014.05.017.CrossRefPubMedGoogle Scholar
  16. 16.
    Yang TK, Hsieh JT, Chen SC, Chang HC, Yang HJ, Huang KH. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. Urology. 2012;80(5):1093–7.  https://doi.org/10.1016/j.urology.2012.08.002.CrossRefPubMedGoogle Scholar
  17. 17.
    Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54(6):1379–84.  https://doi.org/10.1016/j.eururo.2007.11.026.CrossRefPubMedGoogle Scholar
  18. 18.
    Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS One. 2014;9(1):e85588.  https://doi.org/10.1371/journal.pone.0085588.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wada N, Matsumoto S, Kita M, Hashizume K, Kakizaki H. Improvement of overactive bladder symptoms and bladder ischemia with dutasteride in patients with benign prostatic enlargement. LUTS. 2015;7:37.PubMedGoogle Scholar
  20. 20.
    Cartwright R, Mangera A, Tikkinen KA, Rajan P, Pesonen J, Kirby AC, et al. Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men. Eur Urol. 2014;66(4):752–68.  https://doi.org/10.1016/j.eururo.2014.01.007.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tacklind J, Fink HA, MacDonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010;(10):CD006015.  https://doi.org/10.1002/14651858.CD006015.pub3.
  22. 22.
    Kaplan S, He W, Koltun W, Cummings J, Schneider T, Fakhoury A. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol. 2013;63(1):158–65.  https://doi.org/10.1016/j.eururo.2012.07.003.CrossRefPubMedGoogle Scholar
  23. 23.
    • Drake MJ, Sokol R, Coyne K, Hakimi Z, Nazir J, Dorey J, et al. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study. BJU Int. 2016;117(1):165–72.  https://doi.org/10.1111/bju.13162. The addition of the anticholinergic medication solifenacin to the alpha-blocker tamsulosin resulted in a significant improvement in LUTS compared to tamsulosin alone. The reduction in the urgency as measured by the Total Urgency Frequency Score (TUFS) and health-related quality of life.CrossRefPubMedGoogle Scholar
  24. 24.
    Gong M, Dong W, Huang G, Gong Z, Deng D, Qiu S, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015;31(9):1781–92.  https://doi.org/10.1185/03007995.2015.1074067.CrossRefPubMedGoogle Scholar
  25. 25.
    Griebling TL. Overactive bladder in elderly men: epidemiology, evaluation, clinical effects, and management. Curr Urol Rep. 2013;14(5):418–25.  https://doi.org/10.1007/s11934-013-0367-0.CrossRefPubMedGoogle Scholar
  26. 26.
    • Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015;193(3):921–6.  https://doi.org/10.1016/j.juro.2014.09.091. The addition of mirabegron 50 mg to daily tamsulosin significantly improved symptoms of overactive bladder compared to tamsulosin alone in men with BPE and urgency at least once per week.CrossRefPubMedGoogle Scholar
  27. 27.
    Wagg A, Cardozo L, Nitti V, Castro-Diaz D, Auerbach S, Blauwet M, et al. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43(5):666–75.  https://doi.org/10.1093/ageing/afu017.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Lewis Katz School of Medicine at Temple UniversityPhiladelphiaUSA

Personalised recommendations